Streptococcus pneumoniae is one of the key pathogens responsible for otitis media (OM), 25 the most common infection in children and the largest cause of childhood antibiotic 26 prescription. Novel therapeutic strategies that reduce the overall antibiotic consumption 27 due to OM are required because although widespread pneumococcal conjugate 28 immunization has controlled invasive pneumococcal disease, overall OM incidence has not 29 decreased. Biofilm formation represents an important phenotype contributing to the 30 antibiotic tolerance and persistence of S. pneumoniae in chronic or recurrent OM. We 31 investigated the treatment of pneumococcal biofilms with nitric oxide (NO), an endogenous 32 signaling molecule and therapeutic agent that has been demonstrated to trigger biofilm 33 dispersal in other bacterial species. We hypothesised that addition of low concentrations of 34 NO to pneumococcal biofilms would improve antibiotic efficacy and higher concentrations 35 exert direct antibacterial effects. Unlike in many other bacterial species, low 36 concentrations of NO, did not result in S. pneumoniae biofilm dispersal. Instead, treatment 37 of both in vitro biofilms and ex vivo adenoid tissue samples (a reservoir for S. pneumoniae 38 biofilms) with low concentrations of NO enhanced pneumococcal killing when combined 39 with amoxicillin-clavulanic acid, an antibiotic commonly used to treat chronic OM. 40
4
Infections occur following a breach of the mucosal epithelia subsequent to 70 colonization and despite being a prerequisite for infection, little is known about how 71 pneumococci colonize and persist in the nasopharynx. However, a growing body of 72 literature suggests that bacterial biofilm development plays a prominent role in 73 colonization and disease. In situ investigation of paediatric middle ear biopsies indicated 74 that pneumococcal biofilms were present on the middle ear mucosal epithelium in children 75 with chronic OM but not in children without chronic OM (8, 9) . S. pneumoniae biofilms have 76 also been identified in situ on adenoid mucosal epithelia from children undergoing 77 adenoidectomy for the treatment of infective (chronic OM) or inflammatory (obstructive 78 sleep apnoea -OSA) otolaryngological disease consistent with the adenoid serving as a 79 reservoir of pathogens that may contribute to infection under circumstances that favor 80 middle ear infection (10, 11) . More recently, pneumococcal biofilms have been investigated 81 with animal models and epithelial cell models (12) (13) (14) (15) . 82
Biofilms are highly adaptive surface-associated microbial aggregates that allow 83 bacteria to survive the diverse stressful conditions encountered in the host such as nutrient 84 limitation and host immune responses (16) (17) (18) (19) . The increased tolerance of biofilm bacteria 85 to conventional antibiotic therapeutic concentrations compared with their planktonic 86 counterparts also poses a significant problem in clinical settings, as does their propensity 87 to acquire further antimicrobial resistance via horizontal gene transfer, underscoring the 88 need for novel therapeutic strategies to limit the pneumococcal biofilm phenotype during 89 disease (20, 21) . 90
Nitric oxide (NO) is an important signaling molecule that is ubiquitous in both 91 eukaryotes and prokaryotes, bridging the boundaries between host and pathogen. In the 92 5 human host, NO plays an important role in the innate immune response and is produced by 93 inducible nitric oxide synthases (iNOSs) in epithelial and phagocytic cells with its 94 production resulting in damage to bacterial cell membranes and DNA (22) . Bacteria have 95 also been shown to possess NOSs that oxidise L-arginine to produce the low concentrations 96 of NO observed in several species (23, 24) . Multiple regulatory systems have been 97 identified that mediate the diverse responses of bacteria to NO, including conferring 98 protection from oxidative stress and playing a role in toxin biosynthesis (23, 25) . In 99 biofilms, however, low concentrations of exogenous NO have been shown to trigger a 100 dispersal response in several bacterial species including Pseudomonas aeruginosa, 101
Escherichia coli and Staphylococcus epidermidis, a response associated with increased 102 antibacterial efficacy when used as an adjuvant in conjunction with antibiotics (26) (27) (28) . 103 Furthermore, NO-releasing nanoparticles and gaseous NO have been shown to exert potent 104 antimicrobial effects against P. aeruginosa, Streptococcus pyogenes and Enterococcus 105 faecalis (29) (30) (31) . 106
Previous investigations into the role of NO in pneumococcal infection have given 107 conflicting results. In a murine pneumonia model NO was found to be associated with 108 increased bacterial loads and reduced survival during bacteremia in wild-type mice but not 109 in NOS2-deficient mice. In contrast during pneumonia following intranasal infection NO 110 decreased pneumococcal viability in the lung in both mouse strains via a direct 111 antibacterial effect (32). 112
Because several studies using biofilm models have shown that low concentrations of 113 NO trigger release of bacteria from the biofilm in various bacterial species we hypothesized 114 that adjunctive NO treatment would also improve the efficacy of antibiotic killing of 115 6 pneumococci in biofilms. We tested this hypothesis using in vitro and ex vivo pneumococcal 116 biofilms. Biochemical studies and a high-throughput quantitative proteomic approach were 117 utilized to interrogate possible mechanisms of action. 118 119
Methods 120
Bacterial strains and growth conditions. Clinical isolates of Streptococcus pneumoniae 121 serotypes 14 (ST124), 19F and 23F (33), and the laboratory strain D39 (serotype 2) were 122 selected to evaluate the in vitro antibacterial efficacy of NO and antibiotic adjunctive 123 treatment. Strains were subcultured from frozen stocks onto Columbia blood agar (CBA) 124 plates (Oxoid, U.K.) as described (33) . Briefly, cultures were incubated at 37 o C/5% CO2 and 125 colonies re-suspended in fresh Brain Heart Infusion (BHI) broth (Oxoid, U.K.) for 126 experiments. 127
128 Planktonic experiments. Flat-bottomed 96-well culture plates (Fisher Scientific, U.K.) 129 were inoculated with ~1.0 x 10 7 bacteria per well (mid-exponential planktonic cultures) 130 grown in BHI. All treatments were prepared in BHI. Sodium nitroprusside dihydrate (SNP) 131 was added to wells for final concentrations ranging from 1 μM to 10 mM; diethylamine 132 NONOate (DEA/NO; sodium salt), sodium nitrate (NaNO3), sodium nitrite (NaNO2) and 133 potassium cyanide (KCN; all Sigma-Aldrich, U.K.) were added at a final concentration of 1 134 mM, and carboxy-PTIO potassium salt and L-methionine (both Sigma-Aldrich, U.K.) were 135 added at final concentrations of 50 μM and 1 mM respectively. BHI was added in place of 136 treatments for all untreated controls. BHI alone was used to measure background changes 137 in absorbance. Cultures were incubated at 37 o C/5% CO2 and absorbance (OD595) 7 measured every 30 min over 2 hours using an EZ Read 400 spectrophotometer (Biochrom) 139 (n=3). 140
141
In vitro biofilm experiments. For biofilm formation mid-exponential planktonic cultures 142 grown in BHI were used to inoculate individual wells of untreated polystyrene 6-well 143 plates (1 x 10 8 cells per well) (Corning Incorporated, Costar, U.S.A.), and supplemented 144 with fresh BHI diluted 1:5 in distilled H2O. Cultures were incubated at 37 o C/5% CO2 with 145 replacement of warm, fresh diluted 1:5 BHI daily for 2 to 7 days. 146
Prior to treatment medium was removed and biofilms washed twice using diluted 147 1:5 BHI. NO donor (SNP and DEA/NO) treatments were prepared fresh in diluted 1:5 BHI 148 and added to wells at final concentrations ranging from 100 nM to 1 mM. For adjuvant 149 experiments amoxicillin + clavulanic acid (AMC) was added at a final concentration of 150 300/60 μg/ml. Biofilms were incubated at 37 o C/5% CO2 for 2 hours after which the NO 151 donors or inhibitors were removed and the remaining biofilm rinsed twice with diluted 1:5 152 BHI. Biofilms were resuspended in Hank's balanced salt solution (HBSS) as described (20) . 153
Briefly, biofilms were scraped and vortexed, both resuspended biofilms and removed 154 supernatants were diluted in HBSS, spot plated onto CBA plates and incubated at 37 o C/5% 155 CO2. To assess total biofilm biomass 100 μl of the resuspended biofilms were diluted 10-156 fold in 1:5 BHI and turbidity measured by absorbance (OD595) using a Jenway 6300 157 spectrophotometer. All assays were performed on 48 h biofilms using 2 technical replicates 158 of 2 biological replicates (n=4). Biofilms were treated with 1 mM SNP in 1:5 BHI or 1:5 BHI (untreated control) at 37 o C/5% 177 CO2 for 2 hours then processed for SEM as described (33). Biofilms were imaged using an 178 FEI Quanta 200 scanning electron microscope. 179 180 Protein extraction and iTRAQ (isobaric tag for relative and absolute quantitation) 181 labelling. Comparative analyses of protein expression between biofilms treated with 100 182 μM SNP for 2 h at 37 o C/5% CO2 and untreated biofilms were performed on 3 technical 183 9 replicates of 3 biological replicates. Protein extraction and iTRAQ labelling were performed 184 as described (33). 185 186 Mass spectrometry, peak list generation, and database searching. Mass spectrometry, 187 peak list generation and database searching were performed as previously described (33). 188
Inclusion criteria for quantitative analysis were set at ≥3 peptide matches, ≥50 protein 189 score, ≥5% sequence coverage (p < 0.05). Comparative protein data with >1.3 and <0.77 190 ratios were identified as having differential expression. For qualitative identification the 191 inclusion criteria were 2 peptide matches, ≥50 protein score, and ≥5% sequence coverage. Fig. 1 ). Measurement of biofilm biomass using turbidity, and viability using 218 colony forming unit (CFU) enumeration, respectively, indicated that treatment with low 219 concentrations of NO (100 nM to 100 μM SNP) did not have a similar effect on 48h 220 pneumococcal biofilms. Treatment with 1 mM SNP however, resulted in a significant 221 reduction in the biomass and a 3-log reduction in the number of viable cells remaining 222 within the biofilm (p≤0.001). These results suggested that at 1mM SNP treatment may 223 either be triggering the release of S. pneumoniae from the biofilm or had a direct 224 bactericidal effect. To distinguish between these possibilities the number of viable cells 225 present in the biofilm supernatant was measured following treatment with 1 mM SNP. 226
Results indicated that there was a significant reduction in planktonic pneumococcal cells 227 suspended in the supernatant as well as in the biofilm following NO treatment (Fig. 2,  228 p≤0.05). Since NO treatment of biofilms formed by other bacterial species typically results 229 in increased numbers of bacterial CFUs in the supernatant (24) these data indicated that 230 treatment with higher concentrations of SNP had a direct antibacterial killing effect. 231 Furthermore, both SEM and CLSM imaging of biofilms treated with 1 mM SNP 232 demonstrated no significant change in biofilm ultrastructure following treatment 233 confirming the lack of dispersal ( Fig. 3a-b , 3e-f). CLSM imaging did, however, demonstrate 234 a reduction in the number of viable cells remaining within the biofilm following treatment, 235 commensurate with the observed 3-log reduction in CFUs ( Fig. 3c-d ). To confirm that 236 higher NO concentrations were toxic for pneumococcus, mid-exponential planktonic 237 cultures were treated with the same range of concentrations of SNP. Cultures treated with 238 SNP concentrations between 1 μM to 10 mM for 2 hours showed a significant reduction in 239 growth with 500 μM to 5 mM SNP (p≤0.05), and complete cessation of growth with 240 concentrations greater than 5 mM ( Fig. 4) . 241
242
The response of S. pneumoniae to treatment with SNP was mediated by NO. Having 243 determined that both planktonic and biofilm pneumococci responded to SNP treatment, we 244 next wished to confirm that the response was indeed mediated by NO and not due to other 245 NO metabolites, intact SNP or SNP breakdown products other than NO. Treatment with 1 246 mM KCN, a control for the possible effect of cyanide anion liberation from the SNP 247 molecule, caused no reduction in pneumococcal growth confirming that the reduction in 248 viability compared with untreated bacteria was not due to cyanide toxicity (p=0.528; Fig.  249 5a). Moreover, treatment with 1 mM DEA/NO, an alternative NO-donor molecule that is 250 chemically and mechanistically distinct from SNP, resulted in a significant decrease in 251 12 growth, similar in extent to treatment with 1 mM SNP (p=0.013, Fig, 5a ), whilst treatment 252 with the NO-scavenger cPTIO abrogated the response to SNP (p=0.008, Fig. 5b ). These 253 results indicated that the response to SNP treatment was In contrast, treatment with 1 mM nitrate (p=0.321) or nitrite (p=0.078) failed to 255 significantly reduce pneumococcal growth, indicating that the oxidative breakdown 256 products of NO were not responsible for the observed reduction in viability ( Fig. 5a ). Since 257 peroxynitrite (ONOO -) is an extremely toxic molecule that can be produced by reaction of 258 NO with superoxide (O2 -) to cause damage to DNA, proteins and lipids (24, 29), we further 259 tested whether ONOOtoxicity might be involved in reducing pneumococcal viability 260 during SNP treatment by using the ONOOscavenger L-methionine. Indeed, the response to 261 SNP was also reduced by the presence of L-methionine (p=0.005) suggesting that 262 extracellular ONOOformation secondary to reaction with O2 -might be responsible for the 263 bactericidal effects of higher concentrations of NO on pneumococcal cells (Fig. 5c ). with the NO donor alone resulted in a 2-log reduction in viable bacteria, whereas treatment 277 of 23F biofilms resulted in a 3-log reduction (Fig. 6 ). AMC treatment alone resulted in a 3-278 log reduction in ST124 and 23F biofilm viability, and a 2-log reduction in 19F and D39 279 biofilm viability (Fig. 6 ). Combined NO/AMC treatment, however, resulted in a 3-log 280 reduction in 19F and D39, a 5-log reduction in ST124, and complete killing of 23F when 281 compared with untreated biofilms (Fig. 6) , and a significant reduction in viable 282 pneumococci in biofilms compared with antibiotic treatment alone (p < 0.05). 283
284
Combined antibiotic and NO treatment enhanced ex vivo killing of S. pneumoniae on 285 adenoid tissue. Adenoids have been shown to act as a reservoir for S. pneumoniae and 286 biofilm bacteria, and may provide a source for infection in some cases of chronic otitis 287 media (10, 11, 36) . Following research ethics committee approval and informed parental 288 consent (NHS REC 09/H0501/74) we subsequently examined adenoid tissue ex vivo that 289 was culture positive for S. pneumoniae from children <12 years of age undergoing 290 adenoidectomy for the treatment of suspected inflammatory or infective ENT disease to 291 evaluate the effect of NO on S. pneumoniae colonized mucosal epithelia (Fig. 7) . Adenoid 292 sections (n=11) were treated with 100 μM of SNP alone, 300/60 μg/ml AMC alone, or 293 treated with both NO and AMC to determine if NO adjunctive therapy increased antibiotic 294 efficacy (Fig. 7) . Treatment with 100 μM of the NO-donor SNP alone did not significantly 295 Previous data from our lab demonstrated that a total of 112 proteins were differentially 308 expressed during biofilm development using iTRAQ (inclusion criteria ≥3 peptide matches; 309 >5% sequence coverage and a 50+ protein score; p<0.05) (33). Of these, 13 proteins were 310 differentially expressed in established pneumococcal biofilms treated with NO for 2 h, 311 compared with biofilms treated with HBSS alone (Fig. 8 ). Eighty five percent (11/13) of 312 these proteins were involved in S. pneumoniae translation or metabolism (Figure 9a ). Five 313 ribosomal proteins, all of which demonstrated significantly decreased expression in the 314 biofilm phenotype, exhibited increased expression following NO treatment, suggesting a 315 modulation of translational capacity similar to planktonic levels (33). Additionally, 6 316 metabolism-associated proteins were differentially expressed following NO treatment: 3-317 ketoacyl-(acyl-carrier-protein) reductase and PTS system fructose-specific II ABC 318 components were upregulated upon NO treatment, whereas arginine deiminase (ArcA), a 319 15 PTS system mannose specific IID component, and 2 individual alcohol dehydrogenases 320 exhibited decreased expression following NO treatment. The significant reduction in ArcA 321 expression is of particular interest given its >4-fold increase in expression during biofilm 322 growth (33). Two other proteins, a SPFH domain-containing protein and a hypothetical 323 protein were also identified as having increased expression following NO treatment. These 324 data were further supported by the qualitative identification of 12 proteins with 325 differential expression following NO treatment including 7 associated with pneumococcal 326 metabolism ( Figure 9b ). 327
328

Discussion 329
Consistent with other studies, S. pneumoniae biofilms were more tolerant to 330 antibiotic treatment than planktonic pneumococci, including an antibiotic commonly used 331 to treat otitis media (13, 20, 37) . However, pneumococcal biofilm antibiotic tolerance was 332 significantly diminished (by up to 2 logs) when accompanied by adjunctive treatment with 333 a low concentration of NO. Additionally, we demonstrated biochemically that reduced 334 viability of pneumococci in planktonic and biofilm growth conditions was mediated by NO, 335 and the oxidative breakdown products of NO, nitrite and nitrate, did not mimic this effect. 336
Although NO treatment reduced in vitro pneumococcal biofilm CFUs, our data suggest that 337 the anti-pneumococcal effect was not due to a dispersal of bacteria. Rather, higher 338 concentrations of NO demonstrated a direct antibacterial effect on pneumococcal growth. 339
Treatment with 1 mM SNP resulted in a decrease in biofilm viability by up to 3 logs, and in 340 the number of viable cells in the surrounding supernatant. These data were commensurate 341 with CLSM and SEM imaging which demonstrated no obvious changes in biofilm 342 16 ultrastructure, but did reveal a significant reduction in biofilm viability. A similar response 343 was observed using the structurally distinct NO donor, DEA/NO. The reduced antibacterial 344 response in the presence of the NO scavenger cPTIO, and the lack of response to nitrite and 345 nitrate, indicated that the antimicrobial effects were indeed NO-mediated, and not 346 associated with the formation of NO3and NO2which have also been shown to increase 347 antibiotic efficacy in P. aeruginosa biofilms (38). The specificity of the NO-mediated 348 response, along with the reduction in the planktonic growth rate observed with ≥500 μM of 349 SNP, suggest a direct effect on growth and/or regulation of metabolism. 350
We also investigated the hypothesis that low concentrations of NO could enhance 351 antibiotic efficacy in the treatment of pneumococcal biofilms. In vitro S. pneumoniae 352 biofilms were more tolerant than planktonic pneumococci to AMC, an antibiotic commonly 353 used to treat pneumococcal infections, commensurate with other studies (20, 21) . Results 354 indicated that the addition of 1 mM SNP significantly enhanced antibiotic efficacy by 1 to 2 355 logs in each of four strains tested, three of which represent serotypes (14, 19F and 23F) 356 that are predominantly isolated from paediatric ENT patients and are associated with 357 developing antibacterial recalcitrance (34, 35) . Thus, when combined with NO, antibiotic 358 tolerance within the biofilm was significantly diminished. 359
Pneumococcal interactions with epithelial cells have been shown to be important for 360 colonization and biofilm formation (12, 13) , and pneumococci are commonly present on 361 adenoids from children with chronic OM or OSA (10, 11). We therefore used adenoid upper 362 respiratory mucosal epithelial tissue colonized with pneumococci to further determine if a 363 combination of NO and AMC might enhance pneumococcal killing using a lower 364 concentration than for in vitro biofilms. Treatment of ex vivo adenoid tissue culture 365 positive for pneumococcus and rinsed to remove unattached bacteria, resulted in a 366 significant reduction in pneumococcal CFUs on adenoid sections treated with antibiotic 367 alone, but not NO-donor alone on treated tissue from the same adenoid sample. When 368 combined however, NO/AMC treatment resulted in a significantly enhanced reduction in 369
CFUs. These results suggest that low-concentrations of NO rendered biofilm pneumococci 370 more susceptible to antibiotic killing. These results are also consistent with other data 371
showing that NO reduced S. pneumoniae viability in vivo using iNOS knock-out mice (32). 372
The difference in susceptibility to S. pneumoniae bacteremia and lung infection between 373 wild-type and iNOS -/-mice following intravenous infection versus intranasal infection may 374 be due to the differential effects of inducible and constitutive NO production by endothelial 375 and epithelial cells, suggesting that NO concentrations in the host are tissue dependent and 376 regulated locally, and that NO in different mucosal sites is important in anti-pneumococcal 377 host responses. 378 NO is constitutively synthesised in the respiratory epithelium and upregulated in 379 response to infection or inflammation (39). Since S. pneumoniae is highly adapted to the 380 upper airway, a compartment characterised by higher constitutive NO concentrations 381 compared with the lower airways as evidenced by exhaled breath analysis (40), it is likely 382 that this bacterium has the ability to respond to NO. Moreover, since epithelial cells also 383 produce iNOS, we speculate that exogenous NO may combine with endogenous NO levels to 384 achieve the higher concentrations of NO sufficient to produce an enhanced anti-385 pneumococcal response observed in vitro. 386 NO signaling has been shown to elicit different responses in bacterial biofilms, 387 however its role in mediating dispersal from a biofilm by the reversal of a genetically 388 18 determined program inducing biofilm development via cyclic di-GMP (c-di-GMP) has 389 garnered significant interest due to its potential as a treatment strategy for biofilm-390 associated infections (24). In the model biofilm bacterium P. aeruginosa the NO dispersal 391 response results in increased motility and metabolic activity characteristic of the 392 planktonic (colonizing) phenotype allowing propagation to new sites within an 393 environmental niche (41). The single cell phenotype, as well as the increased metabolic 394 and replicative capacity associated with the dispersed planktonic bacteria, are 395 hypothesized to reduce biofilm antibiotic tolerance following NO treatment. Treatment of 396 pneumococcal biofilms with low concentrations of the NO donor, SNP (100 nM to 100 μM), 397
shown to disperse biofilms of other bacterial species resulted in no significant changes in 398 biomass or viability at these concentrations. This is unsurprising since S. pneumoniae is a 399 non-motile bacterium, which lacks proteins possessing the common EAL, GGDEF and HD-400 GYP domains that are involved in the turnover of the secondary messenger c-di-GMP 401 known to mediate dispersal in other bacteria (27, 28) . 402
Rather, proteomic analyses suggested that NO induced a shift to a planktonic-like 403 profile in a subset of proteins, notably those involved in metabolism and translation. 404
Proteomic analyses of S. pneumoniae remaining within biofilms following treatment with a 405 low concentration (100 μM) of NO indicated that 13 of 112 quantitatively identified 406 proteins were differentially expressed, indicating that NO was not directly cytotoxic at 407 concentrations of 100 μM. The increased expression of five ribosomal proteins indicated 408 up-regulation of translational capacity, which was previously shown to be substantially 409 down-regulated in established pneumococcal biofilms (33). We previously hypothesized 410 19 that the decreased translation exhibited by the biofilm phenotype may contribute to 411 antibiotic tolerance in the biofilm mode of growth in S. pneumoniae (33, 41, 42) . 412
Six additional proteins differentially expressed after NO treatment play a role in 413 pneumococcal metabolism. Arginine deiminase (ArcA) and two alcohol dehydrogenases 414 (Adh) were notably decreased. In our previous study, expression of these proteins was 415 markedly increased during biofilm formation, and may compensate for the dramatic 416 reduction in glycolytic activity observed in S. pneumoniae biofilms by up-regulating 417 arginine and pyruvate metabolism (33). Similar to the differential expression of 418 translational proteins, the increased expression of metabolic proteins following NO 419 treatment suggested that pneumococcus differentially modulates metabolism in planktonic 420 and biofilm modes of growth. Qualitatively, seven other metabolic proteins exhibited 421 differential expression following NO treatment, compared with untreated biofilms. 422
However these proteins were below the threshold of >3 peptides required for inclusion in 423 the quantitative iTRAQ dataset. Nonetheless, taken together these data suggest that while 424 high concentrations of NO elicit a direct antibacterial effect, low dose NO may be involved 425 in regulation of metabolism via a currently unknown signaling pathway. 426
The decreased expression of arginine deiminase following NO treatment is of 427 particular interest. Regulation of S. pneumoniae arginine metabolism appears to be distinct 428 from other bacteria and involves the regulators ArgR1, ArgR2 and AhrC (43, 44) . ArgR1 is a 429 transcriptional regulator of the arginine deminase system (ADS) consisting of arginine 430 deiminase (arcA), ornithine carbamoyltransferase (arcB) and carbamate kinase (arcC) that 431 mediate arginine acquisition and virulence in pneumococcus. Abrupt changes in arginine 432 concentrations were recently shown to induce differential transcription of >450 genes in 433 20 Streptococcus gordonii, many of which were involved in adhesion and biofilm development 434 (45) . Furthermore, the difference in the effect of NO on two of the strains of pneumococcus 435 used in our experiments is consistent with D39 and Serotype 14 having variable 436 disruptions in arginine regulators ArgR1 and ArgR2 (43, 44) . 437
We speculate that NO may play a novel role in arginine metabolism and biofilm 438 development in S. pneumoniae, and in regulating growth in pneumococcus. Our results 439 suggest that low concentrations of NO modulate pneumococcal growth, possibly making 440 dormant bacteria within the biofilm metabolically active and more susceptible to antibiotic 441 killing. However, an alternative explanation is that the production of OONOmay contribute 442 to the antibacterial effects of NO on pneumococcus since the antibacterial effect was 443 reduced in the presence of the peroxynitrite (OONO -) scavenger L-methionine. Elevated 444 OONOlevels have also been found to be associated with the dispersal response and cell 445 death in P. aeruginosa (27) . Peroxynitrite is a potent pro-oxidant and cytotoxic species 446 produced by the interaction of superoxide (O2 -) and NO. Compromised pneumococcal 447 superoxide dismutase (SOD) activity may lead to enhanced formation of O2and 448 subsequent reaction with host NO leading to the production of OONO -, a reaction that 449 normally takes place in human macrophages (46) . Peroxynitrite was a putative mediator of 450 NO induced cytotoxic damage in pneumococcal infected microglial cell cultures in vitro and 451 in vivo using pneumococcal mutants for pyruvate oxidase (spxB), and the arginine 452 metabolism mutant carB in mice (22) . Intriguingly, these authors made the novel 453 observation that pneumococcus can release NO, suggesting that NO is an endogenous 454 21 pneumococcal metabolite. Our previous proteomic analyses indicated pyruvate oxidase, 455 which produces H2O2, was also markedly upregulated in pneumococcal biofilms (33) . 456
A MerR-like transcriptional factor NmlRsp required for NO defense was identified in 457 S. pnuemoniae D39 using the NO donor S-nitrosoglutathione (GSNO) (47). There was no 458 evidence of a MER-like transcriptional protein in our proteomic data, however the role of 459
NmlRsp was subsequently noted to have broader functional roles including a role in H2O2 460 production and in arginine biosynthesis (48). 461
The NO donor SNP has been widely utilized for a number of clinical applications, 462 primarily through its use as a vasodilator, however, prolonged treatment and/or high 463 doses have been suggested to pose a risk of cyanide-mediated cytotoxicity (49, 50) . The 464 decomposition of SNP to cyanide has also been shown to be slow (<2.5% over 72 h) when 465 protected from direct exposure to high intensity/natural light (51). For the purpose of our 466 initial study SNP was used as a suitable NO-donor to explore the actions of NO on 467 pneumococcal biofilms since relatively low doses were applied for a short period (26, 27) . 468 Furthermore, treatment with equimolar concentrations of KCN had no effect on 469 pneumococcal growth indicating that any observed responses to SNP were not the result of 470 cyanide toxicity (52). However, future studies investigating NO-mediated anti-471 pneumococcal effects with alternative donors, such as Cephalosporin-3´-diazeniumdiolate 472 NO-Donor Prodrugs, which have been specifically designed to release NO at sites of 473 bacterial infection may offer better choices for clinical use (53). 474
The results of our study are consistent with other studies showing high 475 concentrations of NO were toxic to bacteria including pneumococcus (32). However, to our 476 knowledge our study is the first to show that: 1) planktonic and biofilm S. pneumoniae 477 22 responded differentially to low and high concentrations of NO; 2) the anti-pneumococcal 478 response was not induced by nitrite or nitrate, but was NO specific; 3) unlike other 479 bacteria, low concentrations of NO did not elicit a dispersal response by biofilm S. S. pneumoniae serotype 14 exponential planktonic cultures were treated with the nitric 693 oxide (NO) donors SNP, DEA/NO, nitrate and nitrite, and the CNanion control potassium 694 cyanide (KCN) over 2 hours. Significant decreases in the growth rate were observed upon 695 treatment with two independent NO donors, SNP and DEA/NO, indicating that the response 696 was NO-mediated. KCN treatment had no effect on growth rate confirming the response to 697 SNP was not CNmediated (p=0.528). Sodium nitrate (p=0.321) and sodium nitrite 698 (p=0.078) treatments also had no effect on growth rate suggesting that nitrate and nitrite, 699 respectively, were not utilised as sources of NO. Finally, the addition of b) the NO-700 scavenger carboxy-PTIO, and c) the peroxynitrite scavenger L-methionine reduced the 701 response to SNP treatment suggesting the response may be mediated by either NO or 702 peroxynitrite. *≤0.05; **≤0.01; ***≤0.001. 703 
